Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma

rafenib: a new treatment for BRAF-V600 mutated advanced melanoma Review (2488) Total Article Views Authors: Fisher R, Larkin J Published Date August 2012 Volume 2012:4 Pages 243 - 252 DOI: http://dx.doi.org/10.2147/CMAR.S25284 Received: 06 May 2012 Accepted: 20 June 2012 Published: 08 August 2012 Rosalie Fisher, James Larkin Department of Medical Oncology, Royal Marsden Hospital, London, United Kingdom Abstract: The BRAF inhibitor, vemurafenib, has demonstrated improved progression-free and overall survival compared with chemotherapy in a randomized trial, and represents a new standard of care in patients with advanced melanoma harboring a BRAF-V600 mutation. A BRAF-V600 mutation is identified in approximately half of patients with cutaneous melanoma, and is unequivocally a biomarker predictive of profound clinical benefit for these patients. However, acquired vemurafenib resistance is a major clinical challenge and therapy is not yet curative. A substantial body of translational research has been performed alongside clinical trials of vemurafenib, providing key insights into the molecular basis of response and resistance. This review summarizes the development of vemurafenib for the treatment of BRAF-V600 mutant melanoma and discusses how knowledge of critical signaling pathways will be applied for its optimal clinical use in future.